Literature DB >> 10922995

Interleukin-4 regulates macrophage interleukin-12 protein synthesis through a c-fos mediated mechanism.

S Roy1, R Charboneau, D Melnyk, R A Barke.   

Abstract

BACKGROUND: Interleukin-4 (IL-4) treatment after lipopolysaccharide (LPS) induction inhibits macrophage (Mphi) IL-12 synthesis; however, IL-4 pretreatment (PreTx) primes the Mphi for increased LPS-induced IL-12 production. In this study we study the role of c-fos in the IL-4 priming of Mphi IL-12 synthesis.
METHODS: With a murine in vitro peritoneal M phi model, we studied the effect of either c-fos deficiency (wild type, WT; homozygous c-fos knockout, Homo KO) or c-fos overexpression to study the role of c-fos in IL-4 priming of LPS-induced M phi IL-12 synthesis.
RESULTS: (1) We first show that IL-4 PreTx results in a 72% decrease in Mphi c-fos mRNA compared with vehicle PreTx. (2) With respect to IL-12 p70 protein, IL-4 PreTx in the WT group increased LPS-induced Mphi IL-12 p70 2.2-fold compared with vehicle PreTx. Compared with vehicle PreTx in the WT group, vehicle PreTx in the Homo KO group followed by LPS stimulation resulted in a 2.8-fold increase in IL-12 p70 in the Homo KO group. IL-4 PreTx did not significantly increase IL-12 p70 over vehicle PreTx in the Homo KO group. (3) We studied the effect of c-fos overexpression on LPS-induced Mphi IL-12 production when primed with IL-4. Overexpression of c-fos completely inhibited IL-4 primed LPS-induced IL-12 p70 protein synthesis.
CONCLUSIONS: These data demonstrated that down-regulation of c-fos is an integral part of the IL-4 priming process for Mphi IL-12 production.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10922995     DOI: 10.1067/msy.2000.108063

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  8 in total

1.  Interleukin-12: an update on its immunological activities, signaling and regulation of gene expression.

Authors:  Jianguo Liu; Shanjin Cao; Sunjung Kim; Elaine Y Chung; Yoichiro Homma; Xiuqin Guan; Violeta Jimenez; Xiaojing Ma
Journal:  Curr Immunol Rev       Date:  2005-06

2.  Alternative activation of macrophages by IL-4 impairs phagocytosis of pathogens but potentiates microbial-induced signalling and cytokine secretion.

Authors:  Audrey Varin; Subhankar Mukhopadhyay; Georges Herbein; Siamon Gordon
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

3.  Identifying candidate genes for discrimination of ulcerative colitis and Crohn's disease.

Authors:  Lian-Jie Lin; Ying Zhang; Yan Lin; Yu Jin; Chang-Qing Zheng
Journal:  Mol Biol Rep       Date:  2014-09-03       Impact factor: 2.316

4.  PI3K-γ inhibition ameliorates acute lung injury through regulation of IκBα/NF-κB pathway and innate immune responses.

Authors:  Dong Im Kim; So Ri Kim; Hee Jung Kim; Su Jeong Lee; Heung Bum Lee; Seoung Ju Park; Mie-Jae Im; Yong Chul Lee
Journal:  J Clin Immunol       Date:  2011-12-24       Impact factor: 8.317

5.  SPLUNC1 deficiency enhances airway eosinophilic inflammation in mice.

Authors:  Jyoti V Thaikoottathil; Richard J Martin; Peter Y Di; Maisha Minor; Stephanie Case; Bicheng Zhang; Gongyi Zhang; Hua Huang; Hong Wei Chu
Journal:  Am J Respir Cell Mol Biol       Date:  2012-04-12       Impact factor: 6.914

Review 6.  Regulation of interleukin-12 gene expression and its anti-tumor activities by prostaglandin E2 derived from mammary carcinomas.

Authors:  Maki Mitsuhashi; Jianguo Liu; Shanjin Cao; Xiaoyan Shi; Xiaojing Ma
Journal:  J Leukoc Biol       Date:  2004-05-03       Impact factor: 4.962

7.  Lead effects on development and function of bone marrow-derived dendritic cells promote Th2 immune responses.

Authors:  Donghong Gao; Tapan K Mondal; David A Lawrence
Journal:  Toxicol Appl Pharmacol       Date:  2007-04-12       Impact factor: 4.219

8.  Absence of interleukin-4 determines less severe pulmonary paracoccidioidomycosis associated with impaired Th2 response.

Authors:  Adriana Pina; Rita C Valente-Ferreira; Eugênia E W Molinari-Madlum; Celidéia A C Vaz; Alexandre C Keller; Vera L G Calich
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.